Optimising Antibody-Drug Conjugate Safety: Mechanisms, Monitoring and Management of Toxicities 2026

Conference Details

Date: 09 September 2026

Time: 18:30

Duration: 1 day

Location: Online

Cost: Register online for more information.

Organiser: ESMO - European Society for Medical Oncology

Conference Website

Conference Description

Chair's welcome

Welcome to this ESMO Therapeutic Landscapes webinar on Optimising Antibody–Drug Conjugate Safety. This session will focus on the recognition, prevention, and management of antibody–drug conjugate-related toxicities, with particular attention to interstitial lung disease and ocular adverse events.

The programme will begin with a presentation on prevention and risk mitigation strategies for ADC-related toxicities, outlining patient- and treatment-related risk factors and evidence-based supportive measures. This will be followed by a focused session on ADC-related interstitial lung disease, addressing early clinical and radiological recognition, differential diagnosis, and practical management strategies. The final lecture will explore ADC-related ocular toxicity, including identification, grading, and multidisciplinary management approaches.

The Discussion and Q&A segment will provide an opportunity to critically evaluate safety considerations, assess implementation challenges in daily practice, and discuss strategies to optimise treatment continuity while safeguarding patient outcomes.

Thank you for joining this webinar. We look forward to a highly informative and interactive discussion.

Dr Liliana Ascione, Webinar Chair

Learning Objectives

Recognise patient- and treatment-related risk factors for antibody–drug conjugate (ADC)-related toxicities and apply evidence-based preventive and supportive strategies, including for gastrointestinal and haematological adverse events.
Describe the mechanisms and pathogenesis underlying ADC-related interstitial lung disease (ILD) and ocular toxicity.
Identify early clinical and radiological features of ADC-related ILD and ocular toxicity, apply appropriate grading systems, and differentiate these events from alternative aetiologies.
Implement evidence-based management strategies for ADC-related ILD and ocular toxicity, including treatment interruption, corticosteroid use, and criteria for safe rechallenge.